CD5 B cells and B-cell malignancies

Current Opinion in Hematology

Volumn 6, Issue 1, 1999, Pages 30-36

  Lydyard, Peter M ^a   Jewell, Andrew P ^b   Jamin, Christoph ^c   Youinou, Pierre Y ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; GLYCOPROTEIN GP 39; LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR;

B CELL LEUKEMIA; B LYMPHOCYTE; CHROMOSOME 13Q; CHRONIC LYMPHATIC LEUKEMIA; GENE MUTATION; HUMAN; PATHOGENESIS; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

ANTIGENS, CD5; APOPTOSIS; B-LYMPHOCYTES; CHRONIC DISEASE; EPITOPES; HUMANS; KARYOTYPING; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL;

EID: 0032939598     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199901000-00006     Document Type: Review

References (107)

1. 1 Boumsell L, Bernard A, Lepage V, Degos L, Lemerle J, Dausset J: Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T cells. Eur J Immunol 1978, 8:900-904.
2. 2 Caligaris-Cappio F, Gobbi M, Bofill M, Janossy G: Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med 1982, 155:623-628.
3. 3 Plater-Zyberk C, Maini RN, Lam K, Kennedy TD, Janossy G: A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukaemia. Arthritis Rheum 1985, 28:971-974.
4. 4 Youinou PY, MacKenzie L, Jouquan J, Le Goff P, Lydyard PM: CD5 positive B cells in patients with rheumatoid arthritis: phorbol ester mediated enhancement of detection. Ann Rheum Dis 1987, 46:17-22.
5. 5 Kantor A: A new nomenclature for B cells. Immunol Today 1991, 12:388.
6. 6 Youinou P, Jamin C, Lydyard PM: Pleiotropic roles for CD5 on B cells: a hypothesis. Immunol Today 1998, in press.
7. 7 Youinou P, MacKenzie L, Lamour A, Jamin C, Lydyard PM: CD5-positive B lymphocytes in autoimmunity. Isr J Med Sci 1993, 29:874-876.
8. 8 Kipps TJ: The CD5 B cell. Adv Immunol 1989, 47:117-185.
9. 9 Solvason N, Kearney JF: The human fetal omentum: a site of B cell generation. J Exp Med 1992, 175:397-404.
10. 10 Erkeller-Yuksel FM, Denys V, Yuksel B, Hannet I, Hulstaert F, Hamilton C, et al.: Age-related changes in human lymphocyte sub-populations. J Pediatr 1992, 120:216-222.
11. 11 Lydyard P, Youinou P, Cooke A: CD5-positive B cells in rheumatoid arthritis and chronic lymphocytic leukemia. Immunol Today 1987, 8:37-39.
12. 12 Donno M, Burgio VL, Tacchetti C, Favre A, Augliera A, Zupo S, et al.: Subepithelial B cells in the human palatine tonsil: 1. morphological, cytochemical and phenotypic characterization. Eur J Immunol 1996, 26:2035-2042.
13. 13 Antin JH, Ault KA, Rappeport JM, Smith BR: B lymphocyte reconstitution after human bone marrow transplantation: Leu-1 antigen defines a distinct population of B lymphocytes. J Clin Invest 1987, 80:325-332.
14. 14 De-La-Calle-Martin O, Badell I, Garcia A, Gelpi C, Casamitjana N, Estella J, Rodriguez-Sanchez JL: B cells and monocytes are not developmentally affected in a case of reticular dysgenesis. Clin Exp Immunol 1997, 110:392-396. This report discusses how autologous CD5+ B cells develop in a patient with reticular dysgenesis after allogeneic bone marrow transplantation.
15. 15 Spencer J, Choy M, Hussell T, Papadaki L, Kington JP, Isaacson PG: Properties of human thymic B cells. Immunology 1992, 75:596-600.
16. 16 Donze HH, Lue C, Julian BA, Kutteh WH, Kantele A, Mestecky J: Human peritoneal B-1 cell and the continuous ambulatory peritoneal dialysis on peritoneal and peripheral blood mononuclear cell (PBMC) composition and immunoglobulin levels. Clin Exp Immunol 1997, 109:356-361.
17. 17 Nisitani S, Murakami M, Akmizu T, Okino T, Ohmori K, Mori T, et al.: Preferential localization of human CD5+ B cells in the peritoneal cavity. Scand J Immunol 1997, 46:541-545.
18. 18 Kipps TJ, Vaughan JH: Genetic influence on the levels of circulating CD5+ B lymphocytes. J Immunol 1987, 139:1060-1064.
19. 19 Kourtis AP, Ibegbu CC, Lee FK, Vogler L, Philips K, Nahmias AJ: Decrease in CD5+ B lymphocytes in children with the DiGeorge anomaly. Scand J Immunol 1997, 46:281-283. This article shows the importance of the thymus in the development of B1 cells.
20. 20 Knight KL, Becker RS: Molecular basis of the allelic inheritance of rabbit immunoglobulin VH allotypes: implications for the generation of antibody diversity. Cell 1990, 60:963-970.
21. 21 Dilwith R, Wicher K: CD5+ and CD5-B1-like lymphocytes in healthy guinea pig. Clin Immunol Immunopathol 1997, 85:143-150.
22. 22 Appleyard GD, Wilkie BN: Characterisation of porcine CD5-and CD5+ B cells. Clin Exp Immunol 1998, 111:225-230.
23. 23 Cukrowska B, Sinkora J, Rehakova Z, Sinkora M, Splichal I, Tuckova L, et al.: Isotype and antibody specificity of spontaneously formed immunoglobulins in pig fetuses and germ-free piglets: production by CD5-B cells. Immunology 1996, 88:611-617.
24. 24 MacKenzie LE, Youinou PY, Hicks R, Yüksel B, Mageed RA, Lydyard PM: Auto and polyreactivity of IgM from CD5+ and CD5-cord blood B cells. Scand J Immunol 1991, 33:329-335.
25. 25 Chen ZJ, Wheeler CJ, Shi W, Wu AJ, Yarboro CH, Gallagher M, Notkins AL: Polyreactive antigen binding B cells are the predominant cell type in the newborn repertoire. Eur J Immunol 1998, 28:989-994.
26. 26 Neron S, Lemieux R: CD5+ B cell-dependent regulation of the murine T-cell independent immune response against human blood group A antigen. Immunol Invest 1997, 26:631-647.
27. 27 Wuttke NJ, Macardle PJ, Zola H: Blood group antibodies are made by CD5+ and by CD5-B cells. Immunol Cell Biol 1997, 75:478-483.
28. 28 Parker W, Yu PB, Holzknecht ZE, Lundberg K, Buckley RH, Platt JL: Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B cell lineage and development. J Clin Immunol 1997, 17:311-321.
29. 29 Velupillai P, Secor WE, Horauf AM, Harn DA: B-1 cell (CD5+B220+) outgrowth in murine shistosomiasis is genetically restricted and is largely due to activation by polyactosamine sugars. J Immunol 1997, 158:338-344.
30. 30 Buza J, Sileghem M, Gwakisa P, Naessens J: CD5+ B lymphocytes are the main source of antibodies reactive with non-parasite antigens in Trypanosoma congolense-infected cattle. Immunology 1997, 92:226-233.
31. 31 Taniguchi O, Miyajima H, Hirano T, Noguchi M, Ueda A, Hashimoto H, et al.: The Leu-1 B-cell subpopulation in patients with rheumatoid arthritis. Clin Exp Immunol 1987, 7:441-448.
32. 32 Arinbjarnarson S, Jonsson T, Steinsson K, Sigfusson A, Jonsson H, Geirsson A, et al.: IgA rheumatoid factor correlates with changes in B and T lymphocyte subsets and disease manifestations in rheumatoid arthritis. J Rheumatol 1997, 24:269-274.
33. 33 Youinou P, MacKenzie L, Le Masson G, Papadopoulos NM, Jouquan J, Pennec YL, et al.: CD5-expressing B lymphocytes in the blood and salivary glands of patients with primary Sjögren's syndrome. J Autoimmun 1988, 1:185-194.
34. 34 Smith HR, Olson RR: CD5+ B lymphocytes in systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 1990, 17:833-835.
35. 35 Ye YL, Suen JL, Chen YY, Chiang BL: Phenotypic and functional analysis of activated B cells of autoimmune NZB×NZW F1 mice. Scand J Immunol 1998, 47:122-126. This article discusses how B cells at different stages of activation in autoimmune NZB×NZW F1 mice express different characteristics and functions.
36. 36 Alfreta A, Ferri GM, Amaroso A, Leri O, Pellegrino C, Guido F, et al.: CD5 B cells in autoimmune and non-autoimmune thyroid functions. Endocr Res 1997, 23:81-94.
37. 37 Kung AW, Jones BM: A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy. J Clin Endocrinol Metab 1998, 83:514-518.
38. 38 De Fillippo G, Pozzi N, Cosentini E, Cavalcanti M, Carel JC, Tamasi S, et al.: Increased CD5+CD19+ B lymphocytes at the onset of type 1 diabetes in children. Acta Diabetol 1997, 34:271-274.
39. 39 Berglundh T, Liljenberg B, Tarkowski A, Lindhe J: Local and systemic TCR V gene expression in advanced periodontal disease. J Clin Periodontol 1998, 25:125-133.
40. 40 Chan EY, Lawton JW, Lie AK, Lau CS: Autoantibody formation after allogeneic bone marrow transplantation: correlation with the reconstitution of CD5+ B cells and occurrence of graft-versus-host-disease. Pathology 1997, 29:184-188.
41. 41 Ravindranath RM, Ravindranath MH, Graves MC: Augmentation of natural antiganglioside IgM antibodies in lower motor neuron disease (LMND) and role of CD5+ B cells. Cell Mol Life Sci 1997, 53:750-758.
42. 42 Monteverde A, Ballare M, Pileri S: Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryo-globulinaemia. Springer Semin Immunopathol 1997, 19:99-110.
43. 43 Martins-Filho OA, Dutra WO, Freeman GL, Silveira AM, Rabello A, Colley DG, et al.: Flow cytometric study of blood leucocytes in clinical forms of human schistosomiasis. Scand J Immunol 1997, 46:304-311.
44. 44 Aruffo A, Bowen MA, Patel DD, Haynes BF, Starling GC, Gebe JA, Bajorath J: CD6-ligand interactions: a paradigm for SRCR domain function? Immunol Today 1997, 18:498-504.
45. 45 Gebe JA, Kiener PA, Ring HZ, Li X, Francke U, Aruffo A: Molecular cloning, mapping to human chromosome 1 q21-q23, and cell binding characteristics of Spalpha, a new member of the scavenger receptor cysteine-rich (SRCR) family of proteins. J Biol Chem 1997, 272:6151-6158.
46. 46 Lankester AC, van Scijndel GM, Cordell J, van Noesel CJ, van Lier RA: CD5 is associated with the human B cell antigen receptor complex. Eur J Immunol 1994, 24:812-816.
47. 47 Jamin C, Le Corre R, Lydyard PM, Youinou PY: CD5+ B cells: differential capping and modulation of IgM and CD5. Scand J Immunol 1996, 43:73-80.
48. 48 O'Rourke L, Tooze R, Fearon DT: Co-receptors of B lymphocytes. Curr Opin Immunol 1997, 9:324-329.
49. 49 Bikah G, Carey J, Ciallella JR, Tarakhovsky A: CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 1995, 274:1906-1909.
50. 50 Cyster JG, Goodnow CC: Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection. Immunity 1995, 2:13-24.
51. 51 Tarakhovsky A: Bar Mitzvah for B-1 cells: how will they grow up? J Exp Med 1997, 185:981-984.
52. 52 Rickert RC, Rajewsky, Roes J: Impairment of T-cell dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995, 376:352-355.
53. 53 Ahearn JM, Fisher MB, Croix D, Georg S, Ma M, et al.: Disruption of the Cr2 locus results in a reduction of B1a cells and an impaired B cell response to T-dependent antigen. Immunity 1996, 4:251-262.
54. 54 Namata F, Hitoshi Y, Uehara S, Takatsu K: The xid mutation plays an important role in delayed development of murine acquired immunodeficiency syndrome. Int Immunol 1997, 9:139-146.
55. 55 Van de Velde H, von-Hoegen I, Luo W, Parnes JR, Thielemans K: The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 1991, 351:662-665.
56. 56 Biancone L, Bowen MA, Lim A, Aruffo A, Andres G, Stamenkovic I: Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes. J Exp Med 1996, 184:811-819.
57. 57 Posposil R, Mage RG: CD5 and other superantigens as "ticklers" of the B-cell receptors. Immunol Today 1998, 19:106-108.
58. 58 Kaufmann O, Flath B, Spath-Schwalbe E, Possinger K, Dietel M: Immunohistochemical detection of CD5 with monoclonal antibody 4C7 on paraffin sections. Am J Clin Pathol 1997, 108:669-673. Staining of MCL and B-CLL/SLLs on paraffin sections (for CD5: 4C7) and fresh tissue by flow cytometry was directly comparable apart from one presumed blastoid MCL.
59. 59 Dunphy CH, Wheaton SE, and Perkins SL: CD23 expression in transformed small lymphocytic lymphomas/chronic lymphocytic leukemias and blastic transformations of mantle cell lymphoma. Mod Pathol 1997, 10:818-822.
60. 60 Mauvieux L, Canioni D, Hermine O, Valensi F, Radford-Weis I, Azagury M, et al.: Quantitative RNA slot-blot analysis of CCND1/cyclin D expression in suspected mantle cell lymphoma. Leukemia 1998, 12:78-85.
61. 61 Williams ME, Whitefield M, Swerdlow SH: Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. Ann Oncol 1997, 8(suppl):71-73.
62. 62 Taniguchi M, Oka K, Hiasa A, Yamaguchi M, Ohno T, Kita K, Shiku H: De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood 1998, 91:1145-1151. This analysis of VH gene sequence in CD5+ in diffuse large B-cell lymphomas shows a high incidence of somatic mutation and suggests a different cellular origin.
63. 63 Kume M, Suzuki R, Yatabe Y, Kagami Y, Miura I, Miura AB, et al.: Somatic hypermutations in the VH segment of immunoglobulin genes of CD5-positive diffuse large B-cell lymphomas. Jpn J Cancer Res 1997, 88:1087-1093.
64. 64 Kipps TJ: Chronic lymphocytic leukemia. Curr Opin Haematol 1997, 4:268-276.
65. 65 Moreau EJ, Matutes E, A'Hearn RP, Morilla AM, Morilla RM, OwusuAnkomah KA, et al.: Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997, 108:378-382. This article shows that substituting monoclonal antibody SN8 for CD22 in flow cytometric immunophenotyping of 298 patients with CLL and 166 patients with non-CLL using CD5, CD22, CD23, FMC7, and slg, increased the potential to discriminate between these patient groups.
66. 66 Thompson AA, Talley JA, Do NH, Kagan HL, Kunkel L, Berenson J, et al.: Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Blood 1997, 90:1387-1394. This article shows that the low or undetectable levels of slg expressed by B-CLL cells are due to point mutations, insertions, or deletions within the CD79b gene in sequences coding for transmembrane and cytoplasmic domains of the molecule. CD79b is also required for signal transduction and therefore provides an explanation for the loss of BC signaling, characteristic of this leukemia.
67. 67 Molica S, Levato D, Dattilo A, Mannella A: Clinico-prognostic relevance of quantitative immunophenotyping in B-cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins. Eur J Haematol 1998, 60:47-52. This article provides data on numbers of binding sites per cell for CD20 in 93 previously untreated patients and looks at correlations with clinical parameters.
68. 68 Knauf WU, Langenmayer I, Ehlers B, Mohr B, Adorf D, Nerl CH, et al.: Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1997, 27:523-532. This article shows that serum levels of the soluble form of CD23 but not CD25 at initial diagnosis were linked to disease progression.
69. 69 Juliusson G, Merup M: Cytogenetics in chronic lymphocytic leukemia. Semin Oncol 1998, 25:19-26.
70. 70 Acer H, Connor MJ: Detection of trisomy 12 and centromeric alterations in CLL by interphase-and metaphase-FISH. Cancer Genet Cytogenet 1988, 100:148-151.
71. 71 Gahn B, Schafer C, Neef J, Troff C, Feuring-Buske M, Hiddemann W, Wormann B: Detection of trisomy 12 in CD34+ progenitor cell in a patient with chronic lymphocytic leukaemia by fluorescence in situ hybridization. Ann Oncol 1997, 8(suppl 2):55-57. This article shows that CD34+ progenitor cells carry trisomy 12 in patients with B-CLL. This fact may restrict the feasibility of autologous stem cell transplantation in this disease.
72. 72 Kroft SH, Finn WG, Kay NE, Peterson LC: Isolated 13q14 abnormalities and normal karyotypes are associated with typical lymphocyte morphology in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 1997, 107:275-282.
73. 73 Panayiotidis P, Ganeshaguru K, Rowntree C, Jabbar SA, Hoffbrand VA, Foroni L: Lack of clonal BCRA2 gene deletion on chromosome 13 in chronic lymphocytic leukemia. Br J Haematol 1997, 97:844-847.
74. 74 Kalichikov S, Migliazza A, Cayanis E, Fracchiolla NS, Bonaldo MF, Lawton L, et al.: Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics 1997, 42:369-377.
75. 75 Corcoran MM, Rasool O, Liu Y, Iyengar A, Grander D, Ibbotson RE, et al.: Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood 1998, 91:1382-1390.
76. 76 Liu Y, Corcoran M, Rasool O, Ivanova G, Ibbotson R, Grander D, et al.: Cloning of two candidate tumor suppressor genes within a 10kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 1997, 15:2463-2473. This article identifies two novel candidate tumor-suppressor genes on 13q. 13q is a frequent site of mutation in B-CLL.
77. 77 Gardiner AC, Corcoran MM, Oscier DG: Cytogenetic, fluorescence in situ hybridisation, and clinical evaluation of translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia. Genes Chromosomes Cancer 1977, 20:73-81.
78. 78 Dohner H, Stilgenbauer S, Jame MR, Benner A, Weilguni T, Bentz M, et al.: 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997, 89:2516-2522.
79. 79 Neilsen JR, Auer R, White D, Bienz N, Waters JJ, Whitaker JA, et al.: Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997, 11:1929-1932.
80. 80 Karhu R, Knuutila S, Kallioniemi OP, Siltonen S, Aine R, Vilpo L, Vilpo J: Frequent loss of the 11q14-24 region in chronic lymphocytic leukemia: a study by comparative genomic hybridization. Tampere CLL Group. Genes Chromosomes Cancer 1977, 19:286-290.
81. 81 Geisler CH, Phillips P, Christensen BE, Hou-Jensen K, Larsen JK, Plesner NT, et al.: In B-cell chronic lymphocytic leukemia chromosome 17 abnormalities and not trisomy 12 are the single most cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotyping study of 480 unselected newly diagnosed patients. Leuk Res 1997, 21:1011-1023. In an analysis of 560 patients with newly diagnosed untreated B-CLL, chromosomal abnormalities were found significantly more often in patients with atypical presentation (48%) than typical presentation (22%). Chromosome 17 abnormalities were significantly more frequent in atypical CLL, whereas trisomy 12 was present in both typical and atypical B-CLL phoenotype.
82. 82 Takashima T, Itoh M, Ueda Y, Nishida K, Tamaki T, Misawa S, et al.: Detection of 14q32.33 translocation and t(11;14) in interphase nuclei of chronic B-cell leukemia/lymphomas by in situ hybridisation. Int J Cancer 1997, 72:31-38.
83. 83 Lens D, Dyer MJ, Garcia-Marco JM, De-Schower PJ, Hamoudii RA, Jones D, et al.: p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol 1997, 99:848-857.
84. 84 Amiel A, Arbov L, Manor Y, Fejgin M, Elis A, Gaber E, Lishner M: Monoallelic p53 deletion in chronic lymphocytic leukemia detected by interphase cytogenetics. Cancer Genet Cytogenet 1997, 97:97-100.
85. 85 Jewell AP: Interferon alpha, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1996, 21:43-47.
86. 86 Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P: Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998, 91:2387-2396. This article shows that bone marrow stroma selectively supports the survival of B-CLL cells rather than normal B cells. The authors suggest this mechanism may be important in the accumulation of B-CLL cells in the bone marrow.
87. 87 Osorio LM, De Santiago A, Aguilar-Santelises M, Mellstedt H, Jondal M: CD6 ligation modulates the Bcl2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Blood 1997, 89:2833-2841.
88. 88 Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS: Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood 1997, 89:941-947.
89. 89 Lagneaux L, Delforge A, Bron D, Massy M, Bernier M, Stryckmans P: Heterogenous response of B lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukemia: correlation with the expression of TGF-beta receptors. Br J Haematol 1997, 97:612-620.
90. 90 Douglas RS, Woo EY, Capocasale RJ, Tarshis AD, Nowell PC, Moore JS: Altered response to and production of TGF-beta by B cells from autoimmune NZB mice. Cell Immunol 1997, 179:126-137.
91. 91 Karras JG, Wang Z, Huo L, Howard RG, Frank DA, Rothstein TL: Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes. J Exp Med 1997, 185:1035-1042.
92. 92 Frank DA, Mahajan S, Ritz J: B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 1997, 100:3140-3148. This article presents data that shows that STAT molecules were constitutively phosphorylated on serine residues in all samples of B-CLL cells tested.
93. 93 Semichon M, Merle-Beral H, Lang V, Bismuth G: Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Leukemia 1997, 11:1921-1928. This article provides data that suggest that signaling events via the B-cell receptor connect poorly with downstream signaling events via Syk.
94. 94 Tangye SG, Weston KM, Raison RL: Cytokines and cross-linking of slgM augment PMA-induced activation of human leukaemic CD5+ B cells. Immunol Cell Biol 1997, 75:561-567. This article shows that B-CLL cells can respond to cytokines and slgM cross-linking by proliferation in the presence of suboptimal levels of PMA.
95. 95 Diehl LF, Ketchum LH: Autoimmune disease and chronic lymphocytic leukemia: autoimmune haemolytic anaemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998, 25:80-97.
96. 96 Broeker BM, Klajman A, Youinou PY, Jouquan J, Worman CP, Murphy J, et al.: Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1988, 1:469-481.
97. 97 Caligaris-Cappio F: Relationship between autoimmunity and immunodeficiency in CLL. Hematol Cell Ther 1997, 39(suppl 1):S13-S16.
98. 98 Cantwell M, Hua T, Pappas J, Kipps TJ: Acquired CD40 ligand deficiency in chronic lymphocytic leukemia. Nat Med 1997, 3:984-989. This article provides evidence for a functional acquired defect in the ability of activated T cells to express CD40 ligand in the presence of B-CLL cells. The authors suggest this defect may contribute to the development of immunodeficiency in these patients.
99. 99 Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, et al.: Elevated levels of biologically active CD40 ligand in the serum of patients with chronic lymphocytic leukemia. Br J Haematol 1998, 100:135-141.
100. 100 Moss PA, Gillespie G: Clonal populations of T-cells in patients with B-cell malignancies. Leuk Lymphoma 1997, 27:231-238.
101. 101 Reyes E, Prieto A, Carrion F, Garcia-Suarez J, Esquivel F, Guillen C, Alvarez-Mon M: Altered pattern of cytokine production by peripheral blood CD2+ cells from B chronic lymphocytic leukemia patients. Am J Hematol 1998, 57:93-100.
102. 102 Jewell AP, Yong KL: Regulation and function of adhesion molecules in B cell chronic lymphocytic leukemia. Acta Haematol 1997, 97:67-72.
103. 103 Sebestyen A, Kovalsky I, Mihalik R, Gallai M, Bocsi J, Laszlo E, et al.: Expression of syndecan-1 in human B-cell chronic lymphocytic leukaemia. Eur J Cancer 1997, 33:2273-2277. Syndecan-1 is important in the interaction of cells with the microenvironment. This article shows that B-CLL cells express syndecan-1, but not normal B cells.
104. 104 Bergmann L: Present status of purine analogs in the therapy of chronic lymphocytic leukemia. Leukemia 1997, 11S:S29-S34.
105. 105 Mitterbauer M, Hilgenfeld E, Wilfing A, Jager U, Knauf WU: Is there a place for 2-CDA in the treatment of B-CLL? Leukemia 1997, 11S:S35-S37.
106. 106 Decaudin D, Bosq J, Tertian G, Nedellec G, Bennaceur A, Venuat AM, et al.: Phase II trial of fludarabine monophosphate in patients with mantle cell lymphomas. Leukemia 1998, 16:579-583. This article presents data which suggest that fludarabine therapy is not as effective in mantle cell lymphoma as in B-CLL.
107. 107 Flinn IW, Vogelsang G: Bone marrow transplantation for chronic lymphocytic leukemia. Semin Oncol 1998, 25:60-64.